Ixico PLC shares rose on Wednesday, after it said it has won a contract to provide services for a Parkinsonian trial.

Shares in the neuroscience focused advanced analytics company were up 14% to7.38 pence each in London on Wednesday morning.

Ixico said it has been contracted by ‘a top five [contract research organisation] on behalf of a new pharma client’, which it left unnamed. Ixico will provide its imaging biomarker services for a phase three clinical trial for patients with a type of Parkinsonian disorder.

The trial is due to run for just under five years and is worth over £1 million.

Chief Executive Giulio Cerroni said: ‘We are pleased that our expertise in providing imaging analysis and radiological reads across clinical trials for a broadening range of neurodegenerative disorders, is increasingly recognised across the drug development industry and continues to attract new sponsors seeking these expert services.’

Copyright 2024 Alliance News Ltd. All Rights Reserved.